Healthcare / Drug Manufacturers - Specialty & GenericNSE
$26.01
+1.24 (+4.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-89.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
15.2x
↓EV/EBITDA
4.7x
↓ROE
10.8%
↑Gross Margin
43.4%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.5%
FCF CAGR
—
FCF margin
-19.4%
FCF / Net income
-2.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.93B · net income $250.7M · FCF $-567.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.93B | $2.93B | $2.41B | $3.36B | $2.79B |
| Net Income | $250.7M | $250.7M | $-23.9M | $459.6M | $476.6M |
| EBITDA | $335.0M | $335.0M | $57.9M | $591.7M | $551.8M |
| EPS | 4.54 | 4.54 | -2.32 | 9.08 | 9.53 |
| Gross Margin | 43.4% | 43.4% | 46.7% | 39.8% | 30.0% |
| Operating Margin | 12.4% | 12.4% | 19.0% | 16.5% | 18.0% |
| Net Margin | 8.6% | 8.6% | -1.0% | 13.7% | 17.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.10 | 0.07 | 0.03 |
| Cash Flow | |||||
| Free Cash Flow | $-567.7M | $-567.7M | $33.0M | $-89.0M | $68.0M |
| Returns | |||||
| ROE | 10.8% | 10.8% | -1.2% | 25.1% | 42.1% |
| Valuation | |||||
| P/E | 15.21 | 15.21 | — | 11.78 | 8.55 |
| EV/EBITDA | 4.71 | 4.71 | 93.74 | 8.90 | 7.32 |
| P/B | 0.62 | 0.62 | 2.91 | 2.96 | 3.60 |
| Growth & Yield | |||||
| Revenue Growth | 21.2% | 21.2% | -28.3% | 20.4% | — |
| EPS Growth | 295.7% | 295.7% | -125.6% | -4.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-20.2%
EPS terminal req.
$2.31
Spread vs growth
315.9%
5Y implied EPS CAGR
-9.3%
EPS terminal req.
$2.79
Spread vs growth
305.0%
10Y implied EPS CAGR
-0.1%
EPS terminal req.
$4.50
Spread vs growth
295.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.32 → 4.54
Residual
-50.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.